FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the publication of new data in the Journal of Infectious Diseases showing its investigational, high dose, intranasal H3N2 M2SR influenza vaccine candidate substantially enhanced mucosal and serum antibodies against drifted H3N2 influenza viruses. Results showed that M2SR was well-tolerated at all dose levels and may provide substantial protection against infection with highly drifted strains of H3N2 influenza.
“Antigenic drift, or circulating influenza virus strains that do not match the current influenza vaccines, are a serious public health problem, and the H3N2 strain has been particularly difficult to protect against in recent years,” said Yoshihiro Kawaoka, Head of the Influenza Research Institute of the University of Wisconsin-Madison, Professor of the Institute of Medical Science of the University of Tokyo, and an author of the study. “These data suggest that the intranasal M2SR vaccine evaluated in the study may provide significant advantages over existing injected influenza vaccines.”
;
